<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922271</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237ADE02</org_study_id>
    <nct_id>NCT01922271</nct_id>
  </id_info>
  <brief_title>Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>FAST</acronym>
  <official_title>A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 μg o.d.) Compared to Tiotropium (18 µg. o.d.) in Patients With Moderate to Severe COPD (FAST Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further figure out differences of glycopyrronium bromide
      compared to tiotropium in early bronchodilation measured by a comprehensive assessment of
      lung function that includes hyperinflation and specific airway resistance in patients with
      moderate to severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2</measure>
    <time_frame>Day 1</time_frame>
    <description>Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Airway Resistance (sRAW)</measure>
    <time_frame>Day 1</time_frame>
    <description>Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa*s. Whole body plethysmography (Bodybox) is used to measure SRaw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Resistance Capacity (FRCpleth)</measure>
    <time_frame>Day 1</time_frame>
    <description>Functional Resistance Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Volume (RV)</measure>
    <time_frame>Day 1</time_frame>
    <description>Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lung Capacity (TLC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium followed by NVA237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237</intervention_name>
    <description>NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium 18 μg once daily delivered via HandiHaler® device.</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to NVA237</intervention_name>
    <description>Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).</description>
    <arm_group_label>Tiotropium followed by NVA237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to tiotropium</intervention_name>
    <description>Placebo to tiotropium once daily delivered via HandiHaler® device</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Used as resuce medication</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
    <arm_group_label>Tiotropium followed by NVA237</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged ≥40 years

          -  Patients with moderate to severe COPD defined by a post-bronchodilator Forced
             Expiratory Volume in One Second (FEV1)/(FVC) Forced Vital Capacity ratio of &lt;0.70 and
             a post-bronchodilator FEV1 of ≤70% and FEV1 ≥ 30% of predicted normal values.

          -  Current or ex-smokers who have a smoking history of at least 10 pack years.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Patients who have a clinically significant laboratory abnormality at run-in

          -  Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or
             bladder-neck obstruction or moderate to severe renal impairment (GFR &lt;50 ml/min/1,732)
             or urinary retention. (BPH patients who are stable on treatment can be considered).

          -  Patients with any history of asthma

          -  Patients with pulmonary lobectomy or lung volume reduction surgery or lung
             transplantation

          -  Patients receiving medications in the classes listed in the protocol as prohibited.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12687</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22947</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gummersbach</city>
        <zip>51643</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2015</results_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NVA237 Followed by Tiotropium</title>
          <description>Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium Followed by NVA237</title>
          <description>Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PERIOD 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>WASHOUT Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>PERIOD 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NVA237 Followed by Tiotropium</title>
          <description>Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium Followed by NVA237</title>
          <description>Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="7.2"/>
                    <measurement group_id="B2" value="61.7" spread="8.2"/>
                    <measurement group_id="B3" value="61.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2</title>
        <description>Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2</title>
          <description>Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
          <units>liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.490" spread="0.4232"/>
                    <measurement group_id="O2" value="1.453" spread="0.4135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose</title>
        <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose</title>
          <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
          <units>liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.433" spread="0.4110"/>
                    <measurement group_id="O2" value="1.398" spread="0.4092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Airway Resistance (sRAW)</title>
        <description>Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa*s. Whole body plethysmography (Bodybox) is used to measure SRaw.</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Airway Resistance (sRAW)</title>
          <description>Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa*s. Whole body plethysmography (Bodybox) is used to measure SRaw.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
          <units>kilopascal (kPa)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45 min (n=152, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.203" spread="1.8102"/>
                    <measurement group_id="O2" value="4.105" spread="1.8338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min (n=150, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.904" spread="1.4759"/>
                    <measurement group_id="O2" value="3.089" spread="1.4555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.656" spread="1.3062"/>
                    <measurement group_id="O2" value="2.877" spread="1.4130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 30 min (n=151, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.632" spread="1.3152"/>
                    <measurement group_id="O2" value="2.811" spread="1.4065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 30 min (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.643" spread="1.3146"/>
                    <measurement group_id="O2" value="2.756" spread="1.4091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.779" spread="1.4496"/>
                    <measurement group_id="O2" value="2.828" spread="1.4534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Resistance Capacity (FRCpleth)</title>
        <description>Functional Resistance Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Resistance Capacity (FRCpleth)</title>
          <description>Functional Resistance Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45 min (n=152, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.211" spread="1.3086"/>
                    <measurement group_id="O2" value="5.142" spread="1.2656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min (n=150, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.823" spread="1.2517"/>
                    <measurement group_id="O2" value="4.852" spread="1.1812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.769" spread="1.2571"/>
                    <measurement group_id="O2" value="4.725" spread="1.1496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 30 min (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.756" spread="1.2366"/>
                    <measurement group_id="O2" value="4.714" spread="1.1523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h 30 min (n= 150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.736" spread="1.1545"/>
                    <measurement group_id="O2" value="4.676" spread="1.2243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h 30 min (n= 150, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.761" spread="1.2286"/>
                    <measurement group_id="O2" value="4.704" spread="1.1911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Volume (RV)</title>
        <description>Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Volume (RV)</title>
          <description>Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45 min (n=152, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.433" spread="1.2596"/>
                    <measurement group_id="O2" value="4.344" spread="1.1707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min (n=150, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.996" spread="1.1862"/>
                    <measurement group_id="O2" value="4.035" spread="1.0689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.891" spread="1.1997"/>
                    <measurement group_id="O2" value="3.913" spread="1.0281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 30 min (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.910" spread="1.1534"/>
                    <measurement group_id="O2" value="3.903" spread="1.0281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h 30 min (n= 150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.893" spread="1.0486"/>
                    <measurement group_id="O2" value="3.861" spread="1.1058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h 30 min (n= 150, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.970" spread="1.1576"/>
                    <measurement group_id="O2" value="3.895" spread="1.0740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Lung Capacity (TLC)</title>
        <description>Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lung Capacity (TLC)</title>
          <description>Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45 min (n=152, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.380" spread="1.4781"/>
                    <measurement group_id="O2" value="7.335" spread="1.4328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min (n=150, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.255" spread="1.4628"/>
                    <measurement group_id="O2" value="7.274" spread="1.4032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1hr (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.224" spread="1.4294"/>
                    <measurement group_id="O2" value="7.161" spread="1.4015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1hr 30 min (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.227" spread="1.4383"/>
                    <measurement group_id="O2" value="7.165" spread="1.3690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr 30 min (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.203" spread="1.3700"/>
                    <measurement group_id="O2" value="7.149" spread="1.4476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3hr 30 min (n=150, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.240" spread="1.4297"/>
                    <measurement group_id="O2" value="7.149" spread="1.3963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity (IC)</title>
        <description>Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity (IC)</title>
          <description>Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized patients who applied at least one dose of study medication during at least one study period.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45 min (n=152, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.169" spread="0.5548"/>
                    <measurement group_id="O2" value="2.193" spread="0.5583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min (n=150, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.433" spread="0.5934"/>
                    <measurement group_id="O2" value="2.422" spread="0.5996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1hr (n=151, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.455" spread="0.6001"/>
                    <measurement group_id="O2" value="2.435" spread="0.5908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1hr 30 min (n=151, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.472" spread="0.6200"/>
                    <measurement group_id="O2" value="2.457" spread="0.5883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr 30 min (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.467" spread="0.5929"/>
                    <measurement group_id="O2" value="2.474" spread="0.6051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3hr 30 min (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.479" spread="0.6036"/>
                    <measurement group_id="O2" value="2.449" spread="0.5907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NVA237</title>
          <description>ALL patients on NVA237 for Period 1 &amp; Period 2</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium</title>
          <description>ALL patients onTiotropium for Period 1 &amp; Period 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

